Christian J. Camargo, MD, University of Miami Miller School of Medicine, Miami, FL, introduces the 6-month, randomized, placebo-controlled REACTION trial, piloting the use of an oral multi-nutrient combination for age-related cognitive decline (ARCD). The nutrient intervention contains a specific combination of precursors and cofactors for phospholipid biosynthesis (omega-3 fatty acids, uridine, and choline) which is hypothesized to have a beneficial impact on synaptic plasticity and dendritic spine loss. Previous studies in prodromal Alzheimer’s disease have shown the multi-nutrient combination to exert beneficial effects on memory, cognition, and brain atrophy. At data cut-off, 47 participants have been randomized to the oral multi-nutrient combination or placebo on a 1:1 basis. REACTION will primarily assess feasibility of this intervention, while also assessing memory, cognition, and quality of life outcomes. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.
Disclosures
This work was funded by the American Academy of Neurology McKnight Clinical Translational Research Scholarship
